| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 25.05.
| Takeda to Buy Multilab to Gain Sales Network in Brazil | | - | Bloomberg |
| 25.05.
| Japan's Takeda Strikes Brazil Drug Deal | | 1 | WSJ.com |
| 25.05.
| Takeda Pharmaceutical: To Acquire Brazil's Multilab Industria For BRL500M In Cash | | 1 | Nikkei.com |
| 25.05.
| Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil | | 50 | news aktuell |
| Osaka, Japan, And São Jerônimo, Brazil (ots/PRNewswire) - ? Takeda Pharmaceutical Company Limited (Osaka, Japan, "Takeda") and Multilab Industria e Comercio de Produtos Farmaceuticos Ltda. (Rio...
Mehr lesen zu:
Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil | |
| 25.05.
| Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil | | 63 | PR Newswire |
| OSAKA, Japan, and SÃO JERÃ"NIMO, Brazil, May 25, 2012 /PRNewswire/ --

Takeda Pharmaceutical Company Limited (Osaka, Japan, "Takeda") and Multilab Indústria e Comércio de Produtos Farmacêuticos...
Mehr lesen zu:
Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil | |
| 23.05.
| Furiex Confirms Takeda's Announcement on the Acceptance of the European Medicines Agency Submission of Alogliptin for the Treatment of Type 2 Diabetes | | 37 | Business Wire |
| Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that Takeda
Global Research & Development Centre (Europe) Ltd. received confirmation
on the acceptance of the...
Mehr lesen zu:
Furiex Confirms Takeda's Announcement on the Acceptance of the European Medicines Agency Submission of Alogliptin for the Treatment of Type 2 Diabetes | |
| 23.05.
| Millennium and Takeda Announce Presentations for Key Investigational Molecules at American Society of Clinical Oncology Annual Meeting | | 23 | Business Wire |
| -- Presentations highlight first oral proteasome inhibitor in
clinical trials in multiple myeloma patients --
Millennium:
The Takeda Oncology...
Mehr lesen zu:
Millennium and Takeda Announce Presentations for Key Investigational Molecules at American Society of Clinical Oncology Annual Meeting | |
| 23.05.
| Takeda Announces the Acceptance of the European Medicines Agency Submission of Alogliptin for the Treatment of Type 2 Diabetes | | 28 | PR Newswire |
| LONDON and OSAKA, Japan, May 23, 2012 /PRNewswire/ --
Takeda Pharmaceutical Company Ltd. (Takeda) today announced that Takeda Global Research & Development Centre (Europe) Ltd. ("TGRD Europe") received...
Mehr lesen zu:
Takeda Announces the Acceptance of the European Medicines Agency Submission of Alogliptin for the Treatment of Type 2 Diabetes | |
| 22.05.
| Over 90 Percent of Surveyed Hematologist-Oncologists in the U.S. are Aware that Takeda/Millennium's Subcutaneous Velcade is Approved for the Treatment of Myeloma | | 28 | Business Wire |
| Velcade has Swiftly Penetrated All Myeloma Treatment Settings,
According to a Recent BioTrends Report
BioTrends Research Group, one of the world's leading...
Mehr lesen zu:
Over 90 Percent of Surveyed Hematologist-Oncologists in the U.S. are Aware that Takeda/Millennium's Subcutaneous Velcade is Approved for the Treatment of Myeloma | |
| 14.05.
| Takeda Phase III Crohn's disease trial meets primary endpoints | | 3 | Pharma Bus Review |
| 14.05.
| Takeda Falls Most in 14 Months on Forecast: Tokyo Mover | | 8 | Bloomberg |
| 11.05.
| Takeda Announces GEMINI II Trial of Vedolizumab in Patients with Moderately to Severely Active Crohn's Disease Met Primary Endpoints of Improvement in Clinical Remission in Induction and Maintenance Phases | | 52 | Business Wire |
| Patients in the trial had failed at least one conventional therapy
Takeda Pharmaceutical Company Limited (TSE:4502) today announced
top-line results...
Mehr lesen zu:
Takeda Announces GEMINI II Trial of Vedolizumab in Patients with Moderately to Severely Active Crohn's Disease Met Primary Endpoints of Improvement in Clinical Remission in Induction and Maintenance Phases | |
| 01.05.
| R-Tech Ueno: Announcement on the Anticipated Date of the Arbitration Decision against Takeda Pharmaceuticals Company Limited | | 61 | Business Wire |
| R-Tech
Ueno (JASDAQ: 4573) has announced today that it has been notified by
the International Court of Arbitration, International Chamber of
Commerce (ICC), that...
Mehr lesen zu:
R-Tech Ueno: Announcement on the Anticipated Date of the Arbitration Decision against Takeda Pharmaceuticals Company Limited | |
| 26.04.
| Furiex Confirms Takeda's Receipt of Complete Response Letter from the FDA for Alogliptin and Fixed-Dose Combination Alogliptin and Pioglitazone | | 31 | Business Wire |
| Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that Takeda
Pharmaceutical Company Limited issued a news release reporting that
Takeda has received a complete...
Mehr lesen zu:
Furiex Confirms Takeda's Receipt of Complete Response Letter from the FDA for Alogliptin and Fixed-Dose Combination Alogliptin and Pioglitazone | |
| 26.04.
| UPDATE 1-U.S. delays decision on Takeda diabetes drug | | 3 | Reuters.com |
| 26.04.
| Takeda Receives Complete Response Letter from the FDA for Type 2 Diabetes Investigational Therapies Alogliptin and Fixed-Dose Combination Alogliptin and Pioglitazone | | 82 | PR Newswire |
| DEERFIELD, Ill. and OSAKA, Japan, April 25, 2012 /PRNewswire/ --Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Global Research & Development Center...
Mehr lesen zu:
Takeda Receives Complete Response Letter from the FDA for Type 2 Diabetes Investigational Therapies Alogliptin and Fixed-Dose Combination Alogliptin and Pioglitazone | |
| 24.04.
| Zacks Bull and Bear of the Day Highlights: UnitedHealth Group, Citi Trends, AstraZeneca plc, Ardea Biosciences and Takeda Pharmaceutical | | 46 | PR Newswire |
| CHICAGO, April 24, 2012 /PRNewswire/ --Zacks Equity Research highlights UnitedHealth Group (NYSE: UNH) as the Bull of the Day and Citi Trends, Inc. (Nasdaq: CTRN) as the Bear of the Day....
Mehr lesen zu:
Zacks Bull and Bear of the Day Highlights: UnitedHealth Group, Citi Trends, AstraZeneca plc, Ardea Biosciences and Takeda Pharmaceutical | |
| 20.04.
| Takeda und AMAG erhalten ein positives CHMP-Gutachten in Europa für Rienso(R) (Ferumoxytol) zur Behandlung von Eisenmangelanämie bei erwachsenen Patientenmit chronischer Niereninsuffizienz | | 87 | news aktuell |
| London, Osaka, Japan Und Lexington, Massachusetts (ots/PRNewswire) - Takeda Pharmaceutical Company Limited (Takeda) und AMAG Pharmaceuticals, Inc. gaben heute bekannt, dass das Committee for Medicinal...
Mehr lesen zu:
Takeda und AMAG erhalten ein positives CHMP-Gutachten in Europa für Rienso(R) (Ferumoxytol) zur Behandlung von Eisenmangelanämie bei erwachsenen Patientenmit chronischer Niereninsuffizienz | |
| 20.04.
| Takeda and AMAG Receive A Positive CHMP Opinion in Europe for Rienso® (ferumoxytol) for the Treatment of Iron Deficiency Anaemia in Adult Chronic Kidney Disease Patients | | 48 | PR Newswire |
| LONDON, OSAKA, Japan, and LEXINGTON, Massachusetts, April 20, 2012 /PRNewswire/ --
Takeda Pharmaceutical Company Limited (Takeda) and AMAG Pharmaceuticals, Inc. today announced that the Committee...
Mehr lesen zu:
Takeda and AMAG Receive A Positive CHMP Opinion in Europe for Rienso® (ferumoxytol) for the Treatment of Iron Deficiency Anaemia in Adult Chronic Kidney Disease Patients | |
| 17.04.
| Takeda and Metabolon Initiate Research Collaboration to Discover Novel Targets and Biomarkers | | 51 | Business Wire |
| Metabolon, Inc., a diagnostics and services company offering the
industry's leading biochemical profiling technology announces that
Metabolon and Takeda Pharmaceutical...
Mehr lesen zu:
Takeda and Metabolon Initiate Research Collaboration to Discover Novel Targets and Biomarkers | |
